Viridian Therapeutics, Inc./DE Net Change in Cash
Viridian Therapeutics, Inc./DE (VRDN) reported Net Change in Cash of -$47.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$36.04M, a 316.81% decline year-over-year.
- Viridian Therapeutics, Inc./DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $16.62M.
- Viridian Therapeutics, Inc./DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$11.19M.
- Viridian Therapeutics, Inc./DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$67.06M.
- Viridian Therapeutics, Inc./DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $112.79M.
- Viridian Therapeutics, Inc./DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$3.23M.
- Viridian Therapeutics, Inc./DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$52.75M, a 146.57% decline from fiscal 2022.
- Viridian Therapeutics, Inc./DE cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $113.28M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$47.40M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$36.04M 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $112.79M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $70.05M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $17.73M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $16.62M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | -$3.23M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $97.49M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $4.84M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | -$11.19M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | -$52.75M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | -$43.98M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$68.50M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$67.06M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $113.28M 10-K · filed 2025-03-03 | |||
| 2022-09-30 | $301.91M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$11.01M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | -$11.44M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | -$3.60M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $92.98M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | -$18.19M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $592.00K 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $21.05M 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $5.23M 10-Q · filed 2021-11-05 | |||
| 2020-06-30 | $5.74M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $11.26M 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | -$7.76M 10-K · filed 2021-03-26 | |||
| 2019-09-30 | -$7.75M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$8.60M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | -$14.41M 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | -$14.84M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |